Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07484269
PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
Sponsor: Novartis Pharmaceuticals
View on ClinicalTrials.gov
Summary
The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer
Official title: Understanding Drug Utilisation, Treatment Patterns, Clinical Outcomes, and Profile of the Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan for the Treatment of Metastatic Prostate Cancer: a Multicountry, AI-powered Registry (PULSE)
Key Details
Gender
MALE
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
753
Start Date
2026-09-30
Completion Date
2031-07-31
Last Updated
2026-10-30
Healthy Volunteers
No
Conditions
Locations (1)
Novartis Investigative SIte
Basel, Switzerland